Please assess the completion status of the following clinical trial:

Trial Title: Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Non-metastatic primary invasive breast cancer overexpressing HER2 (determined by immunohistochemistry 3+ or positive fluorescence in situ hybridization test) that has been histologically confirmed, adequately excised, axillary node positive or negative, and tumor size at least T1c according to Tumor/Node/Metastasis (TNM) staging~* Completion of at least 4 cycles of (neo-)adjuvant systemic chemotherapy, definitive surgery, and radiotherapy, if applicable~* Known hormone receptor status~* Baseline left ventricular ejection fraction (LVEF) greater than or equal to (≥) 55 percent (%)~Exclusion Criteria:~* Prior invasive breast carcinoma~* Other malignancies except for curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix~* Clinical T4 tumors~* Cumulative doxorubicin exposure greater than (\>) 360 milligrams per meter-squared (mg/m\^2) or epirubicin \>720 mg/m\^2 or any prior anthracyclines unrelated to the present breast cancer~* Peripheral stem cell or bone marrow stem cell support~* Prior mediastinal irradiation except for internal mammary node irradiation for the present breast cancer~* Non-irradiated internal mammary nodes or supraclavicular lymph node involvement~* Prior anti-HER2 therapy for any other reason or other prior biologic or immunotherapy for breast cancer~* Concurrent anti-cancer treatment in another investigational trial~* Serious cardiac or pulmonary conditions/illness, or any other conditions that could interfere with planned treatment~* Poor hematologic, hepatic, or renal function~* Pregnancy or lactation~* Women of childbearing potential or less than 1 year post-menopause unwilling to use adequate contraceptive measures

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observation Arm (Type: NO_INTERVENTION): Participants who have completed definitive surgery and systemic adjuvant chemotherapy will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin will be provided.
- Herceptin 1-Year Arm (Type: EXPERIMENTAL): Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 1 year or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
- Herceptin 2-Year Arm (Type: EXPERIMENTAL): Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 2 years or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.

Based on this trial design, predict the completion outcome and termination type (if applicable).